Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

133.85USD
26 Jun 2017
Change (% chg)

-- (--)
Prev Close
$133.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,913,369
52-wk High
$135.18
52-wk Low
$94.42

Select another date:

Mon, Jun 5 2017

BRIEF-Bluebird Bio, Celgene Corp announce updated clinical results from ongoing first-in-human multicenter study

* Bluebird Bio and Celgene Corporation announce updated clinical results from ongoing first-in-human multicenter study of bb2121 anti-bcma car t cell therapy in relapsed/refractory multiple myeloma at ASCO annual meeting

BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept

* Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

UPDATE 2-Celgene MS drug clears key trial, but disability data falls short

May 22 Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

Celgene's multiple sclerosis drug succeeds in late-stage trial

May 22 Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.

BRIEF-Celgene announces positive results from radiance

* Celgene announces positive results from radiance, the second pivotal phase III trial of oral ozanimod in patients with relapsing multiple sclerosis

Celgene leukemia drug extends survival in early stage trial

Nearly 20 percent of patients with an aggressive form of leukemia experienced complete remission along with prolonged survival from treatment with an experimental Celgene Corp drug, according to data from an early-stage study released on Wednesday.

Celgene leukemia drug extends survival in early stage trial

May 17 Nearly 20 percent of patients with an aggressive form of leukemia experienced complete remission along with prolonged survival from treatment with an experimental Celgene Corp drug, according to data from an early-stage study released on Wednesday.

Celgene 1st quarter sales miss; expects psoriasis drug rebound

Celgene Corp on Thursday reported lower-than-expected first-quarter revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.

UPDATE 3-Celgene 1st quarter sales miss; expects psoriasis drug rebound

April 27 Celgene Corp on Thursday reported lower-than-expected first-quarter revenue with Otezla sales well short of Wall Street estimates, but the U.S. biotechnology company promised the psoriasis drug was poised to rebound.

Select another date:

More From Around the Web